Covid-19 Respiratory Sequelae French Cohort

Study Overview
=================
Brief Summary
-----------------
As the investigators need data on long term outcome of Covid-19, especially respiratory sequelae, a national cohort is required. To better evaluate the potential respiratory sequelae after SARS-CoV-2 infection, it is fundamental to include patients with different management at the acute phase of the Covid-19: ambulatory management, hospitalization in non ICU and in ICU units. That is why the investigators will conduct a national cohort study with all components of french pneumology which will give the investigators the opportunity to include patients in general hospital, in university hospital and in private structure. As it is a real life study, the investigators will include all patients who will have a consultation with a pneumologist for an evaluation 5 to 7 months after a Covid-19 infection whatever their acute disease management. The investigators will collect all available data on Covid-19 acute phase, on patients characteristics and comorbidities, on persistent symptoms after Covid-19, on exams results during the outcome evaluation (CT-scan, 6 min walk test, spirometry and DLCO, blood gas, VO2 max if realized).

Official Title
-----------------
National Epidemiological Cohort to Evaluate Covid-19 Respiratory Sequelae: a French Pneumologist Collaboration.

Conditions
-----------------
COVID-19, Fibrosis, Cohort, Follow-up, Sequelae, Spirometry DLCO

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults, older than 18 SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) in nasopharyngeal swab in patients who are evaluated by a pneumologist 5 to 7 months after their Covid-19 disease Exclusion Criteria: patients for whom follow-up would be difficult owing to psychotic disorder dementia patients who have declined to participate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variation of vital capacity at 5 months after Covid-19 episode |  | at 5 months | 
| Variation of vital capacity at 7 months after Covid-19 episode |  | at 7 months | 
| DLCO alteration at 5 months after Covid-19 episode |  | at 5 months | 
| DLCO alteration at 7 months after Covid-19 episode |  | at 7 months | 
| desaturation during the 6 min walk test |  | at 5 months | 
| desaturation during the 6 min walk test |  | at 7 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variation of FEV1 spirometry parameters |  | at 5 months | 
| Variation of FEV1 spirometry parameters |  | at 7 months | 
| Variation of VC spirometry parameters |  | at 5 months | 
| Variation of VC spirometry parameters |  | at 7 months | 
| Variation of FVC spirometry parameters |  | at 5 months | 
| Variation of FVC spirometry parameters |  | at 7 months | 
| Variation of DLCO spirometry parameters |  | at 5 months | 
| Variation of DLCO spirometry parameters |  | at 7 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, Fibrosis, cohort, follow-up, Sequelae, spirometry DLCO